Merck Reports More Positive Phase 3 Study Results for V114 Vaccine
October 20 2020 - 7:38AM
Dow Jones News
By Colin Kellaher
Merck & Co. on Tuesday reported positive results for its
V114 investigational 15-valent pneumococcal conjugate vaccine in
two additional phase 3 studies.
The Kenilworth, N.J., drug maker said V114 met its primary
immunogenicity objectives and elicited a strong immune response for
all 15 serotypes included in the vaccine, including 22F and 33F,
the two serotypes targeted by V114 but not by the currently
available 13-valent pneumococcal conjugate vaccine.
Merck said V114 was generally well tolerated in both studies,
with a safety profile consistent with that observed in previously
reported studies.
Merck in September said a pair of phase 3 studies evaluating
V114 had met their primary immunogenicity objectives.
The company said its plans for global regulatory licensure
applications, beginning with the U.S. Food and Drug Administration
before the end of the year, remain on track.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 20, 2020 07:23 ET (11:23 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024